Literature DB >> 27616271

Effect of sildenafil on human aromatase activity: From in vitro structural analysis to catalysis and inhibition in cells.

Roberta Baravalle1, Francesca Valetti1, Gianluca Catucci1, Giovanna Gambarotta2, Mario Chiesa3, Sara Maurelli3, Elio Giamello3, Ines Barone4, Stefania Catalano4, Sebastiano Andò4, Giovanna Di Nardo5, Gianfranco Gilardi6.   

Abstract

Aromatase catalyses the conversion of androgens into estrogens and is a well-known target for breast cancer therapy. As it has been suggested that its activity is affected by inhibitors of phosphodiesterase-5, this work investigates the potential interaction of sildenafil with aromatase. This is carried out both at molecular level through structural and kinetics assays applied to the purified enzyme, and at cellular level using neuronal and breast cancer cell lines. Sildenafil is found to bind to aromatase with a KD of 0.58±0.05μM acting as a partial and mixed inhibitor with a maximal inhibition of 35±2%. Hyperfine sublevel correlation spectroscopy and docking studies show that sildenafil binds to the heme iron via its 6th axial water ligand. These results also provide information on the starting molecular scaffold for the development of new generations of drugs designed to inhibit aromatase as well as phosphodiesterase-5, a new emerging target for breast cancer therapy. Copyright Â
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aromatase inhibitors; Breast cancer; Cytochromes P450; Estrogens; Sildenafil

Mesh:

Substances:

Year:  2016        PMID: 27616271     DOI: 10.1016/j.jsbmb.2016.09.003

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  3 in total

1.  Biophysical characterization of Aptenodytes forsteri cytochrome P450 aromatase.

Authors:  Francisco Zarate-Perez; Jesús B Velázquez-Fernández; Gareth K Jennings; Lisa S Shock; Charles E Lyons; John C Hackett
Journal:  J Inorg Biochem       Date:  2018-04-07       Impact factor: 4.155

Review 2.  New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil.

Authors:  Marian Cruz-Burgos; Alberto Losada-Garcia; Carlos D Cruz-Hernández; Sergio A Cortés-Ramírez; Ignacio Camacho-Arroyo; Vanessa Gonzalez-Covarrubias; Miguel Morales-Pacheco; Samantha I Trujillo-Bornios; Mauricio Rodríguez-Dorantes
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

3.  Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents.

Authors:  Pan Pantziarka; Vidula Sukhatme; Sergio Crispino; Gauthier Bouche; Lydie Meheus; Vikas P Sukhatme
Journal:  Ecancermedicalscience       Date:  2018-04-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.